BioLine RX (Israel) Top Management

BioLine RX Management Team Effectiveness

The company has return on total asset (ROA) of (0.2029) % which means that it has lost $0.2029 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3721) %, meaning that it generated substantial loss on money invested by shareholders. BioLine RX's management efficiency ratios could be used to measure how well BioLine RX manages its routine affairs as well as how well it operates its assets and liabilities. BioLine RX holds a total of 922.87 Million outstanding shares. Almost 99.65 percent of BioLine RX outstanding shares are held by general public with 0.25 (percent) owned by insiders and only 0.1 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as BioLine RX in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BioLine RX, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BioLine RX Workforce Comparison

BioLine RX Benchmark Summation

BioLine RX Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BioLine RX often depends on how effective the management is. BioLine RX management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioLine management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioLine management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of BioLine RX's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioLine RX's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of BioLine RX's management manipulating its earnings.

When running BioLine RX's price analysis, check to measure BioLine RX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLine RX is operating at the current time. Most of BioLine RX's value examination focuses on studying past and present price action to predict the probability of BioLine RX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLine RX's price. Additionally, you may evaluate how the addition of BioLine RX to your portfolios can decrease your overall portfolio volatility.